AR028531A1 - Compuestos organicos - Google Patents
Compuestos organicosInfo
- Publication number
- AR028531A1 AR028531A1 ARP010101623A ARP010101623A AR028531A1 AR 028531 A1 AR028531 A1 AR 028531A1 AR P010101623 A ARP010101623 A AR P010101623A AR P010101623 A ARP010101623 A AR P010101623A AR 028531 A1 AR028531 A1 AR 028531A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkoxy
- optionally substituted
- hydrogen
- alkyl
- hydroxyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Un compuesto de la formula (1) en forma libre o de sal, en donde R1 es hidrogeno o alquilo opcionalmente sustituido por hidroxilo, alcoxilo, o tioalquilo, R2 es hidrogeno, alquilo hidroxialquilo, alquilcarboniloxialquilo, alcoxialquilo, alquiltioalquilo, alquenilo, cicloalquilalquilo, heterociclilalquilo, aralquilo, en donde el anillo de arilo del mismo está opcionalmente fusionado con un grupo heterocíclico de 5 miembros, o está opcionalmente sustituido por uno o más sustituyentes seleccionados a partir de alcoxilo, amino, alquilamino, dialquilamino, acilamino, halogeno, aminosulfonilo, alquilaminosulfonilo, dialquilaminosufonilo, alquilsulfonilamino, o dialquilaminosulfonilamino;, R3 es hidrogeno, o alquilo opcionalmente sustituido por hidroxilo, alcoxilo o tioalquilo, R4 es hidrogeno o alquilo, R5 es un grupo quinolinilo, isoquinolinilo, u oxodihidroisoquinolinilo opcionalmente fusionado con un grupo heterocíclico de 5 miembros y opcionalmente sustituido por uno o más sustituyentes seleccionados a partir de halogeno, ciano, hidroxilo, alquilo, hidroxialquilo, alcoxialquilo, alquiltioalquilo, alcoxilo, tioalquilo, alquenilo, alcoxicarbonilo, alquinilo, carboxilo, acilo, un grupo de la formula ûN(R6)R7, arilo opcionalmente sustituido por uno o más sustituyentes seleccionados a partir de halogeno, o alcoxilo o heteroarilo que contiene 5 o 6 átomos del anillo, unidos a través de un átomo de carbono del anillo con átomo de carbono indicado, y R6 y R7 son cada uno independientemente hidrogeno o alquilo opcionalmente sustituido por hidroxilo o alcoxilo, o uno de R6 y R7 es hidrogeno y el otro es acilo, o R6 y R7 junto con el átomo de nitrogeno con el que están unidos denotan un grupo heterocíclico de 5 o 6 miembros. Una composicion farmacéutica, un proceso de preparacion del compuesto y uso del mismo para la fabricacion de un medicamento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0008694.2A GB0008694D0 (en) | 2000-04-07 | 2000-04-07 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR028531A1 true AR028531A1 (es) | 2003-05-14 |
Family
ID=9889516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101623A AR028531A1 (es) | 2000-04-07 | 2001-04-05 | Compuestos organicos |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20030171384A1 (es) |
| EP (1) | EP1268480B1 (es) |
| JP (1) | JP3869725B2 (es) |
| KR (1) | KR100526094B1 (es) |
| CN (1) | CN1176922C (es) |
| AR (1) | AR028531A1 (es) |
| AT (1) | ATE253576T1 (es) |
| AU (2) | AU2001273921B2 (es) |
| BR (1) | BR0109855A (es) |
| CA (1) | CA2403514C (es) |
| CZ (1) | CZ20023305A3 (es) |
| DE (1) | DE60101158T2 (es) |
| DK (1) | DK1268480T3 (es) |
| ES (1) | ES2210169T3 (es) |
| GB (1) | GB0008694D0 (es) |
| HU (1) | HUP0300565A3 (es) |
| IL (1) | IL152078A0 (es) |
| MX (1) | MXPA02009903A (es) |
| MY (1) | MY119238A (es) |
| NO (1) | NO20024741D0 (es) |
| NZ (1) | NZ521361A (es) |
| PE (1) | PE20020228A1 (es) |
| PL (1) | PL212407B1 (es) |
| PT (1) | PT1268480E (es) |
| RU (1) | RU2269529C2 (es) |
| SK (1) | SK14282002A3 (es) |
| TR (1) | TR200400185T4 (es) |
| WO (1) | WO2001077110A1 (es) |
| ZA (1) | ZA200207956B (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| US7019010B2 (en) * | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| PL374552A1 (en) * | 2002-06-12 | 2005-10-31 | F.Hoffmann-La Roche Ag | Amide substituted xanthine derivatives with gluconeogenesis modulating activity |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| CN105001222B (zh) * | 2002-08-21 | 2017-11-07 | 勃林格殷格翰制药两合公司 | 8‑[3‑氨基‑哌啶‑1‑基]‑黄嘌呤化合物，其制备方法及作为药物制剂的用途 |
| DE602004011603T2 (de) * | 2003-02-19 | 2009-01-29 | F. Hoffmann-La Roche Ag | Sulfonamidsubstituierte xanthinderivate zur verwendung als pepck-inhibitoren |
| US7148229B2 (en) | 2003-02-19 | 2006-12-12 | Hoffman-La Roche Inc. | Sulfonamide substituted xanthine derivatives |
| US7247639B2 (en) * | 2003-06-06 | 2007-07-24 | Endacea, Inc. | A1 adenosine receptor antagonists |
| KR100658080B1 (ko) * | 2003-08-26 | 2006-12-15 | 비오이 하이디스 테크놀로지 주식회사 | 백라이트 조립용 지그 |
| TW200605893A (en) * | 2004-02-12 | 2006-02-16 | Novartis Ag | Use of organic compounds |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| AU2005243149A1 (en) * | 2004-05-08 | 2005-11-24 | Novartis International Pharmaceutical Ltd. | 1-Aryl-4-substituted isoquinolines |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
| US7601723B2 (en) * | 2005-02-25 | 2009-10-13 | Pgx Health, Llc | Pyridyl substituted xanthines |
| US20070004745A1 (en) * | 2005-03-25 | 2007-01-04 | Schering-Plough Corporation | Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| ZA200804550B (en) | 2005-11-09 | 2009-08-26 | Combinatorx Inc | Methods, compositions, and kits for the treatment of medical conditions |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| CA2810839A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| JP2010532319A (ja) * | 2007-06-13 | 2010-10-07 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 聴覚障害の処置用のｐｄｅ阻害剤 |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| EP2410855B1 (en) * | 2009-03-26 | 2016-06-01 | Mapi Pharma Limited | Process for the preparation of alogliptin |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| CA2803504C (en) | 2010-06-24 | 2022-08-30 | Boehringer Ingelheim International Gmbh | A combination for diabetes therapy comprising linagliptin and a long-acting insulin |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| AU2012219316A1 (en) * | 2011-02-18 | 2013-10-03 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) |
| DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014071044A1 (en) * | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ−４阻害薬の医学的使用 |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2558162B1 (fr) * | 1984-01-17 | 1986-04-25 | Adir | Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant |
| GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| WO1999062905A1 (en) * | 1998-06-03 | 1999-12-09 | Almirall Prodesfarma, S.A. | 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors |
| GB9828340D0 (en) * | 1998-12-22 | 1999-02-17 | Novartis Ag | Organic compounds |
-
2000
- 2000-04-07 GB GBGB0008694.2A patent/GB0008694D0/en not_active Ceased
-
2001
- 2001-04-05 PL PL358205A patent/PL212407B1/pl unknown
- 2001-04-05 US US10/240,481 patent/US20030171384A1/en not_active Abandoned
- 2001-04-05 AU AU2001273921A patent/AU2001273921B2/en not_active Ceased
- 2001-04-05 PT PT01940294T patent/PT1268480E/pt unknown
- 2001-04-05 MX MXPA02009903A patent/MXPA02009903A/es active IP Right Grant
- 2001-04-05 WO PCT/EP2001/003909 patent/WO2001077110A1/en active IP Right Grant
- 2001-04-05 CN CNB018074898A patent/CN1176922C/zh not_active Expired - Fee Related
- 2001-04-05 MY MYPI20011632A patent/MY119238A/en unknown
- 2001-04-05 KR KR10-2002-7012627A patent/KR100526094B1/ko not_active IP Right Cessation
- 2001-04-05 RU RU2002129557/04A patent/RU2269529C2/ru not_active IP Right Cessation
- 2001-04-05 IL IL15207801A patent/IL152078A0/xx unknown
- 2001-04-05 HU HU0300565A patent/HUP0300565A3/hu unknown
- 2001-04-05 DK DK01940294T patent/DK1268480T3/da active
- 2001-04-05 CZ CZ20023305A patent/CZ20023305A3/cs unknown
- 2001-04-05 TR TR2004/00185T patent/TR200400185T4/xx unknown
- 2001-04-05 PE PE2001000317A patent/PE20020228A1/es not_active Application Discontinuation
- 2001-04-05 BR BR0109855-1A patent/BR0109855A/pt not_active IP Right Cessation
- 2001-04-05 DE DE60101158T patent/DE60101158T2/de not_active Expired - Lifetime
- 2001-04-05 AR ARP010101623A patent/AR028531A1/es not_active Application Discontinuation
- 2001-04-05 NZ NZ521361A patent/NZ521361A/en unknown
- 2001-04-05 SK SK1428-2002A patent/SK14282002A3/sk unknown
- 2001-04-05 AU AU7392101A patent/AU7392101A/xx active Pending
- 2001-04-05 CA CA002403514A patent/CA2403514C/en not_active Expired - Fee Related
- 2001-04-05 AT AT01940294T patent/ATE253576T1/de active
- 2001-04-05 ES ES01940294T patent/ES2210169T3/es not_active Expired - Lifetime
- 2001-04-05 JP JP2001575583A patent/JP3869725B2/ja not_active Expired - Fee Related
- 2001-04-05 EP EP01940294A patent/EP1268480B1/en not_active Expired - Lifetime
-
2002
- 2002-10-02 NO NO20024741A patent/NO20024741D0/no not_active Application Discontinuation
- 2002-10-03 ZA ZA200207956A patent/ZA200207956B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR028531A1 (es) | Compuestos organicos | |
| AR031597A1 (es) | Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3 | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| ES2058630T3 (es) | Derivados de 2-(1-piperazinil)-4-fenilcicloalcanopiridinas, procedimientos de preparacion y composiciones farmaceuticas que los contienen. | |
| AR046200A1 (es) | Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas | |
| AR024634A1 (es) | Composicion farmaceutica estabilizada en forma liofilizada | |
| AR005706A1 (es) | Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico | |
| DK0687253T3 (da) | Hidtil ukendte 4-aminopyridiner, fremgangsmåde til deres fremstilling samt lægemidler indeholdende disse forbindelser | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| AR035548A1 (es) | Compuestos organicos | |
| CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
| CO5280079A1 (es) | Nuevos compuestos | |
| HUP0203136A2 (hu) | Piperazinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| CO5200785A1 (es) | Uso terapeutico de quinazolina | |
| UA72917C2 (en) | Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor | |
| PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
| HUP0302468A2 (hu) | Alfa V integrin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények | |
| ES2066875T3 (es) | Aminoalquilindoles, procedimiento para su obtencion y preparados farmaceuticos que los contienen. | |
| AR006720A1 (es) | Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende | |
| HUP9700328A2 (hu) | Heteroaril-oxazolidinonok, eljárás előállításukra, a vegyületeket tartalmazó gyógyszerkészítmények, alkalmazásuk és köztitermékeik | |
| KR910011895A (ko) | 약제 | |
| AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
| PE20050420A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
| BG103258A (en) | Azinyloxy- and phenoxydiaryl derivatives of carboxylic acids, their preparation and application as mixed eta/etb endothelin-receptor antagonists | |
| CY1107703T1 (el) | Υποκατεστημενες δικετοπιπεραζινες και χρηση αυτων ως ανταγωνιστες οξυτοκινης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |